Immunotherapy resistance of lung cancer  

作　　者：Xin Yu Chaonan Han Chunxia Su 

机构地区：[1]Department of Oncology,Shanghai Pulmonary Hospital&Thoracic Cancer Institute,Tongji University School of Medicine,Shanghai 200433,China

出　　处：《Cancer Drug Resistance》2022年第1期114-128,共15页癌症耐药（英文）

基　　金：supported by National Natural Science Foundation of China(grant number:81874036,82072568);Science and Technology Commission of Shanghai Municipality(19411971100);Shanghai Shenkang Hospital Development Center(SHDC12020110).

摘　　要：In recent years,immunotherapy has made remarkable breakthroughs and brought long-term survival benefits to lung cancer patients.However,a high percentage of patients do not respond to immunotherapy or their responses are transient,indicating the existence of immune resistance.Current studies show that the interactions between cancer cells and immune system are continuous and dynamic.A range of cancer cell-autonomous characteristics,tumor microenvironment factors,and host-related influences account for heterogenous responses.Furthermore,with the identification of new targets of immunotherapy and the development of immune-based combinations,we propose the response strategies to overcome resistance.

关 键 词：IMMUNOTHERAPY resistance mechanisms response strategies 

分 类 号：R73[医药卫生—肿瘤]